restrict the use of Rezulin (troglitazone) for diabetes

The FDA may further restrict the use of Rezulin (troglitazone) for diabetes...due to the risk of liver toxicity.

FDA advisors recommend NOT using Rezulin for monotherapy.

They also want the FDA to require patient package explain the need for frequent liver function tests.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote